CervoMed vs Genelux
CRVO and GNLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRVO and GNLX compare
Genelux is the larger company, worth 3.4 times as much as CervoMed ($86.9M against $25.2M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRVO | GNLX |
|---|---|---|
| Size and price | ||
| Market cap | $25.2M | $86.9M |
| Share price | $1.67 | $1.92 |
| Change, 1 year | −77.0% | −65.2% |
| Change, 5 years | −94.3% | – |
| Beta (5Y) | 3.26 | 0.79 |
| Employees | 15 | – |
| StockData Score | ||
| Total score | 5 | 5 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 76.2× | – |
| P/B | 1.1× (better) | 5.4× |
| FCF yield | – | −33.0% |
| Growth | ||
| Revenue growth (TTM) | −95.7% | – |
| Profitability | ||
| Operating margin | −9407% | – |
| Net margin | −9161% | – |
| Return on equity | −108% (better) | −178% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | – | 2.39 |
| Altman Z-score | −4.99 (better) | −15.04 |
| Piotroski F-score | 1 | 1 |
| Dividends and buybacks | ||
| Buyback yield | – | −21.7% |
| Shareholder yield | 0.00% (better) | −21.7% |
| Ownership | ||
| Held by institutions | 11.6% | 21.7% |
| Held by insiders | 36.9% | 7.7% |
| Insider net buying, 12 months | $3.0M (better) | −$341K |
| Short interest, % of float | 12.7% | 10.9% |
Go deeper
- CRVO stock overview
- CRVO income statement
- CRVO valuation and score
- GNLX stock overview
- GNLX income statement
- GNLX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.